| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
310,240,000 |
| Market
Cap: |
7.12(B) |
| Last
Volume: |
1,927,729 |
Avg
Vol: |
2,408,803 |
| 52
Week Range: |
$19.25 - $24.13 |
|
| Level
I Sector: |
Industrials |
| Level
II Sector: |
Diversified Services |
| Level
III Sector: |
Research Services |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : 17.5 |
| Insider 6 Months : 18.9 |
| Insider 3/6 Months : 36.8 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Exelixis is an oncology-focused biotechnology company that engages in the discovery, development and commercialization of new medicines for cancers. Co.'s products include: CABOMETYX® (cabozantinib) tablets approved for renal cell carcinoma, and for previously treated hepatocellular carcinoma; and COMETRIQ® (cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer. The other products are: COTELLIC® (cobimetinib), an inhibitor of MEK approved as part of a combination regimen to treat forms of melanoma; and MINNEBRO® (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved for the treatment of hypertension in Japan.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
425,000 |
615,000 |
735,409 |
735,409 |
| Total Buy Value |
$8,733,955 |
$12,666,689 |
$15,268,727 |
$15,268,727 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
2 |
3 |
4 |
4 |
| Total Shares Sold |
69,613 |
135,838 |
601,659 |
1,021,249 |
| Total Sell Value |
$1,477,009 |
$2,946,700 |
$12,908,109 |
$20,266,173 |
| Total People Sold |
4 |
6 |
9 |
12 |
| Total Sell Transactions |
5 |
7 |
17 |
28 |
| End Date |
2024-04-25 |
2024-01-23 |
2023-07-25 |
2022-07-25 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Wyszomierski Jack L |
Director |
– • – |
2024-06-04 |
4 |
AS |
$22.00 |
$182,314 |
D/D |
(8,287) |
349,499 |
|
4% |
|
| Wyszomierski Jack L |
Director |
– • – |
2024-05-31 |
4 |
A |
$0.00 |
$0 |
D/D |
18,838 |
357,786 |
|
- |
|
| Beckerle Mary C |
Director |
– • – |
2024-05-31 |
4 |
A |
$0.00 |
$0 |
D/D |
18,838 |
34,262 |
|
- |
|
| Eckhardt Sue Gail |
Director |
– • – |
2024-05-31 |
4 |
A |
$0.00 |
$0 |
D/D |
18,838 |
34,262 |
|
- |
|
| Smith Julie |
Director |
– • – |
2024-05-31 |
4 |
A |
$0.00 |
$0 |
D/D |
10,015 |
15,460 |
|
- |
|
| Papadopoulos Stelios |
Director |
– • – |
2024-05-31 |
4 |
A |
$0.00 |
$0 |
D/D |
18,838 |
1,279,416 |
|
- |
|
| Freire Maria C |
Director |
– • – |
2024-05-31 |
4 |
A |
$0.00 |
$0 |
D/D |
18,838 |
99,257 |
|
- |
|
| Oliver Bob |
Director |
– • – |
2024-05-31 |
4 |
A |
$0.00 |
$0 |
D/D |
18,838 |
37,014 |
|
- |
|
| Heyman Tomas J. |
Director |
– • – |
2024-05-31 |
4 |
A |
$0.00 |
$0 |
D/D |
18,838 |
37,014 |
|
- |
|
| Poste George |
Director |
– • – |
2024-05-31 |
4 |
A |
$0.00 |
$0 |
D/D |
18,838 |
232,745 |
|
- |
|
| Caligan Partners Lp |
See Remarks |
– • – |
2024-05-30 |
4 |
B |
$20.76 |
$4,670,055 |
I/I |
225,000 |
1,525,730 |
2.1 |
8% |
|
| Caligan Partners Lp |
See Remarks |
– • – |
2024-05-28 |
4 |
B |
$20.32 |
$4,063,900 |
I/I |
200,000 |
1,300,730 |
2.1 |
10% |
|
| Poste George |
Director |
– • – |
2024-05-21 |
4 |
S |
$20.96 |
$244,939 |
D/D |
(11,686) |
213,907 |
|
-6% |
|
| Poste George |
Director |
– • – |
2024-05-21 |
4 |
OE |
$19.57 |
$228,695 |
D/D |
11,686 |
225,593 |
|
- |
|
| Smith Julie |
Director |
– • – |
2024-05-21 |
4 |
S |
$21.12 |
$576,154 |
D/D |
(27,280) |
5,445 |
|
-6% |
|
| Papadopoulos Stelios |
Director |
– • – |
2024-05-20 |
4 |
S |
$21.00 |
$240,177 |
D/D |
(11,437) |
1,260,578 |
|
-6% |
|
| Papadopoulos Stelios |
Director |
– • – |
2024-05-20 |
4 |
OE |
$19.57 |
$228,695 |
D/D |
11,686 |
1,272,015 |
|
- |
|
| Senner Christopher J. |
EVP and CFO |
• – – |
2024-05-15 |
4 |
D |
$20.99 |
$636,207 |
D/D |
(30,310) |
721,680 |
|
- |
|
| Morrissey Michael M |
President and CEO |
• • – |
2024-05-15 |
4 |
D |
$20.99 |
$1,552,064 |
D/D |
(73,943) |
964,384 |
|
- |
|
| Aftab Dana |
CSO/EVP Disc & Trans Research |
• – – |
2024-05-15 |
4 |
D |
$20.99 |
$474,479 |
D/D |
(22,605) |
520,990 |
|
- |
|
| Haley Patrick J. |
EVP, Commercial |
• – – |
2024-05-15 |
4 |
D |
$20.99 |
$651,614 |
D/D |
(31,044) |
355,036 |
|
- |
|
| Hessekiel Jeffrey |
EVP, General Counsel & Sec |
• – – |
2024-05-15 |
4 |
D |
$20.99 |
$544,502 |
D/D |
(25,941) |
630,325 |
|
- |
|
| Wyszomierski Jack L |
Director |
– • – |
2024-05-13 |
4 |
AS |
$21.37 |
$233,425 |
D/D |
(10,923) |
338,948 |
|
6% |
|
| Wyszomierski Jack L |
Director |
– • – |
2024-05-13 |
4 |
OE |
$19.57 |
$228,695 |
D/D |
11,686 |
349,871 |
|
- |
|
| Garber Alan M |
Director |
– • – |
2024-03-21 |
4 |
AS |
$24.01 |
$461,112 |
D/D |
(19,205) |
35,703 |
|
-6% |
|
1007 Records found
|
|
Page 1 of 41 |
|
|
0.61 (2.73%) 
